尤瑞克林联合阿托伐他汀治疗对急性脑梗死患者临床疗效、氧化低密度脂蛋白及超敏C反应蛋白的影响

目的 观察尤瑞克林联合阿托伐他汀治疗急性动脉硬化性脑梗死临床疗效及对氧化低密度脂蛋白（ox LDL）、超敏C反应蛋白（hs CRP）的影响。方法 120例按TOAST分型为大动脉粥样硬化性且未进行溶栓取栓的急性脑梗死患者按随机分为对照组60例、观察组60例，两组给予常规治疗，包括抗血小板、神经保护剂、改善血液循环药物，对照组他汀类药物选择阿托伐他汀，20 mg/次，每晚1次；观察组给予阿托伐他汀20 mg，每晚1次，及尤瑞克林治疗，0.15 PNA，加入0.9%生理盐水 100 ml，静点每日1次，连续治疗2周。治疗前、治疗14天后分别进行脑卒中量表（NIHSS）评分，评估临床疗效。治疗前、治疗2周后采用方法测定血浆ox LDL、hs CRP含量。 结果 治疗2周后观察组ox LDL、hs CRP水平明显低于对照组(P＜0.01)。观察组和对照组治疗14天后 NIHSS 评分较治疗前明显降低(P＜0.05) ，观察组NIHSS 评分较对照组显著下降(P＜0.05) 。结论 阿托伐他汀联合尤瑞克林治疗未溶栓取栓的急性脑梗死患者可有效改善神经功能缺损，促进恢复神经功能，效果明显优于常规疗法。

Effects of ureklin combined with atorvastatin on clinical efficacy,ox-LDL and hs-CRP in patients with acute cerebral infarction

Objective To observe the effects of ureklin combined with atorvastatin on clinical efficacy, oxidized low density lipoprotein (ox LDL) and hypersensitive c reactive protein (hs CRP) in patients with acute cerebral infarction (ACI).Methods A total of 120 ACI patients with aortic atherosclerosis but without thrombolysis and thrombectomy according to TOAST classification were randomly divided into control group and observation group, 60 cases in each group. Routine treatment was given to two groups, including anti platelet, neuroprotective agents and drugs that improved blood circulation. The control group was treated with atorvastatin (20 mg/time) and qn. The observation group was treated with atorvastatin(20 mg), qn and ureklin, 0.15 PNA, 0.9% normal saline(100 ml) and qd. Both groups were continuously treated for 2 weeks. The National Institutes of Health Stroke Scale (NIHSS) was used to evaluate the clinical efficacy before and 14 days after the treatment. The ox LDL, hs CPR content were determined before and 14 days after the treatment. Results After 14 days of treatment, ox LDL and hs CRP levels in observation group were significantly lower than those in control group (P<0.01). The NIHSS scores in both groups before the treatment were lower than before (P<0.05), and the score of observation group was significantly lower than that of control group (P<0.05). The clinical efficacy of observation group was better than that of control group (P<0.05). Conclusion Ureklin combined with atorvastatin in the treatment of ACI patients without thrombolysis and thrombectomy can effectively improve the nerve function defect, promote the recovery of nerve function, and its effect is obviously superior to routine treatment.